// Biotech and Pharma Therapeutics
Mayo Clinic Platform Program to Help Clinical Digital Health Startups Succeed
January 21, 2025 / Digital Health Startups / Clinical Workflow Integration / Mayo Clinic Platform / Digital Health Tools
Mayo Clinic Platform_Solutions Studio accelerates digital health solution integration into clinical workflows by providing de-identified clinical data, technical frameworks, and commercialization support, ensuring hospitals can adopt credible, streamlined digital health tools to improve care delivery.
AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025
January 21, 2025 / NauroRestore ACD856 / Alzheimer’s Disease Treatment / Neuroinflammation Biomarkers / Parkinson’s Therapies / Phase 2 Clinical Trials
AlzeCure’s NeuroRestore ACD856, targeting neuroinflammation in Alzheimer’s, will be presented at AD/PD 2025. Preclinical data shows cognitive benefits, neuroprotection, and anti-inflammatory effects, supporting its potential for multiple neurodegenerative diseases. Phase 2 studies are in preparation.
What will 2025 hold for biopharma?
January 21, 2025 / Biopharma 2025 Outlook / Top-selling Incretin Drugs / Obesity and Diabetes Therapies / Keytruda Sales Forecast
Biopharma’s 2025 outlook highlights growth in obesity, cancer, and diabetes therapies, led by incretin drugs like Ozempic and Mounjaro, projected to generate $70B in sales. Keytruda remains top-selling, while FDA approvals and dealmaking may boost recovery.
How Healthcare Leaders Reacted to the 15 Additional Drugs Selected for Medicare Negotiation Program
January 20, 2025 / Medicare Drug Price Negotiation / Inflation Reduction Act Healthcare / Ozempic and Wegovy Affordability / Drug Price Reform
HHS announced 15 drugs for Medicare price negotiation under the Inflation Reduction Act, aiming to reduce costs for conditions like cancer, diabetes, and asthma. Drugmakers oppose, citing innovation risks, while patient advocates praise expanded affordability.
Transforming Our Collective Approach to Alzheimer’s Disease Care Begins with Early and Accurate Diagnosis
January 19, 2024 / Alzheimer’s Early Diagnosis / Blood-based Biomarker Tests / Cognitive Impairment Detection
Early and accurate Alzheimer’s diagnosis is critical to optimizing amyloid-targeting therapies. Innovations like blood-based biomarker tests and expanded access to amyloid PET scans improve diagnostic accessibility, enabling timely treatment and better outcomes for patients with early symptomatic disease.
// 4th Industrial Revolution
How Ambience Is Saving Clinicians from ‘the Perpetual Dread’ of Documentation Overload
January 21, 2025 / AI-powered Clinical Documentation / Ambience Healthcare Platform / Reducing Clinician Burnout / AI Scribe
St. Luke’s Health System is scaling Ambience AI, an AI-powered scribe that automates clinical documentation, reducing clinicians’ documentation time by 39%. This tool enhances patient interactions and alleviates clinician burnout, improving work-life balance.
VA prescribers exempt from DEA’s special telehealth registration
January 21, 2025 / VA Telehealth Exemption DEA / Telemedicine / Veterans Affairs
VA telehealth prescribers are exempt from the DEA’s special registration for controlled substances, leveraging the VA’s integrated system for patient safety. Prescribers must review VA EHR and state PDMP data before prescribing Schedule II-V substances.
Percipio Health Launches AI-Powered Population Health Platform with $20M
January 21, 2025 / AI population Health Platform / Smartphone Health Monitoring / Percipio Health Series A Funding
Percipio Health unveiled its innovative, AI-powered population health platform, backed by $20M in funding. Using smartphone-based AI to monitor health signals like vital signs and cognition, it delivers real-time insights, enabling precise, scalable, and personalized care.
Innovaccer Acquires Humbi AI to Launch AI Actuarial Copilots
January 21, 2025 / Innovaccer Humbi Ai Acquisition / Risk Management Healthcare AI / Intelligence Cloud Expansion
Innovaccer acquired Humbi AI to integrate actuarial expertise into its Healthcare Intelligence Cloud. This enables enhanced risk management, financial performance, and patient outcomes while introducing AI-powered Actuarial Copilots for efficient, data-driven decision-making in value-based care.
UCSF and GE Healthcare launch Care Innovation Hub
January 21, 2025 / GE Care Innovadtion Hub
UCSF and GE Healthcare launched the Care Innovation Hub to advance imaging and precision oncology. The collaboration focuses on AI-driven diagnostic technologies, real-time imaging customization, and treatment monitoring, with applications in neurodegenerative diseases, brain health, and oncology.
// Business & Markets
Absci partners with semiconductor company AMD for AI drug discovery
January 21, 2025 / AI Drug Discovery Partnership / Generative AI Biologics / Drug Discovery
Absci partners with AMD to enhance AI-driven drug discovery using AMD Instinct accelerators and ROCm software. This collaboration supports Absci’s advanced antibody design models and mission to accelerate biologics development, backed by AMD’s $20M investment.
Iris Telehealth Acquires innovaTel to Enhance Telepsychiatry Services
January 21, 2025 / Iris Telehealth /InnovaTel Acquisition / Telepsychiatry / Behavioral Health Provider Shortage
Iris Telehealth acquired innovaTel to expand telepsychiatry services, addressing the U.S. mental health provider shortage. The partnership boosts Iris’ clinician network to over 650 and enhances access to scalable, sustainable behavioral health care across diverse organizations.
DarioHealth closes $25.6M private placement of convertible preferred stock
January 21, 2025 / DarioHealth / Chroic Care Management Platform / GLP-1 Weight Loss / Digital Health Equity Funding
DarioHealth secured $25.6M via a private placement of convertible preferred stock to strengthen its financial position, support profitability by 2025, and expand chronic care management services across B2B, pharma, and Medicare Advantage markets.
Sionna, Odyssey join queue of biotechs testing investors’ IPO interest
January 21, 2025 / Sionna Therapeutics IPO / Odyssey Therapeutics IPO / Immune Disease Precision Therapies
Sionna Therapeutics and Odyssey Therapeutics filed for IPOs to advance cystic fibrosis and immune disease treatments, respectively. Sionna targets CFTR protein stabilization, while Odyssey focuses on precision immune therapies, including RIPK2 inhibitors. Both leverage significant venture funding.
Chinese firms link up with Prolium on bispecific antibody
January 21, 2025 / ICP-B02 / InnoCare KeyMed Prolium Partnership / Oncology Expansion
InnoCare Pharma, KeyMed Biosciences, and their joint venture partnered with Prolium Bioscience for global non-cancer and ex-Asia oncology development of ICP-B02, a CD20xCD3 bispecific antibody, leveraging Prolium’s expertise in biopharma innovation and commercialization.
// Legal & Regulatory
Johnson & Johnson’s Spravato gains FDA nod to be used as a monotherapy
January 21, 2025 / J&J / Spravato / Depression / Major Depressive Disorder
Johnson & Johnson’s Spravato received FDA approval for monotherapy in major depressive disorder (MDD), expanding its use beyond combination therapy. Clinical trials demonstrated rapid symptom improvement, though access remains regulated due to misuse risks.
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
January 21, 2025 / DYNE-101 Fast Track Designdation / Mytonic Dystrophy Type 1 Treatment / FDA
The FDA granted Fast Track designation to Dyne Therapeutics’ DYNE-101 for myotonic dystrophy type 1 (DM1). This investigational antisense oligonucleotide therapy targets toxic RNA to improve splicing and muscle function, currently in the Phase 1/2 ACHIEVE trial.
Sanofi API plant hit with FDA warning letter detailing quality, consistency flubs
January 21, 2025 / Sanofi / FDA / FDA Warning Letter
The FDA issued a warning letter to Sanofi’s Genzyme plant in Framingham, MA, citing failures in API manufacturing quality, contamination investigations, and equipment suitability. Despite the issues, Sanofi asserts drug supply remains uninterrupted as remediation continues.
AstraZeneca, Daiichi’s Enhertu successor gets first FDA OK in breast cancer
January 21, 2025 / Datroway FDA Breast Cancer Approval / AstraZeneca / Trodelvy Competitor Therapy Approval
The FDA approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) for HR-positive, HER2-negative advanced breast cancer after two prior treatments. While efficacy challenges exist, Datroway represents a new third-line therapy option and competes with Trodelvy.
Sanofi’s consumer health arm Opella secures FDA green light to pursue OTC Cialis study
January 21, 2025 / OTC Cialis FDA Approval / Sanofi / Erectile Dysfunction OTC Treatment
Sanofi’s consumer health unit, Opella, received FDA approval to proceed with an actual use trial (AUT) for converting Cialis to an over-the-counter erectile dysfunction treatment, marking the first PDE-5 inhibitor to reach this milestone.
// Research & Development
Catalent to support Galapagos’ decentralized cell therapy approach
January 21, 2025 / Catalent Galapagos CAR-T Partnership / Cell Therapy Manufacturing
Catalent partnered with Galapagos to support decentralized manufacturing of GLPG5101, an investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma, utilizing Catalent’s Princeton facility to facilitate clinical trials in the New Jersey and New York regions.
Boston Scientific sees success in PFA device trial
January 20, 2025 / Boston Scientific / Pulsed Field Ablation System
Boston Scientific’s Advantage AF trial demonstrated the success of its pulsed field ablation (PFA) system in treating paroxysmal atrial fibrillation (AF). The trial met safety and effectiveness endpoints, expanding potential use for persistent AF and posterior wall ablation.
Atara’s Ebvallo and pipeline candidate put on clinical hold in US after partner’s failed plant inspection
January 21 2025 / Atara Biotherapeutics / Pierre Fabre / T-Cell Therapy / Allogeneic Cell Therapy
The FDA placed a clinical hold on Atara Biotherapeutics’ Ebvallo and ATA3219 programs due to compliance issues at a third-party manufacturing facility. Ongoing enrolled patient treatments continue, while Atara collaborates to address the manufacturing concerns.
Study shows benefits and risks from GLP-1RAs
January 21, 2025 / GLP-1 Receptor Agonist Benefits / Ozempic / Wegovy Analysis / Diabetes Obesity / GLP-1 Drugs
A study in Nature Medicine analyzed benefits and risks of GLP-1 receptor agonists (GLP-1RAs) like Ozempic, Wegovy, and Mounjaro. Using VA databases, researchers compared GLP-1RAs with other diabetes treatments, highlighting their growing use in diabetes and obesity care.
NWeight-loss jabs linked to reduced risk of 42 conditions including dementia
January 20, 2025 / Obesity / Diabetes / Pharmaceuticals Industry / Diets and Dieting
GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) reduce risks for 42 conditions, including dementia and psychotic disorders, in people with diabetes. However, they also increase risks for 19 conditions, such as arthritis and kidney stones, requiring further research.
// Politics
NZ gov’t reshuffle prioritises health in 2025
January 21, 2025 / New Zedaland Health Leadership / Simeon Brown / Health Minister / Digital Health Funding Cuts
New Zealand’s health ministry leadership shifted to Simeon Brown, prioritizing timely healthcare access for 2025. Concerns persist over reduced funding for digital health initiatives, risking progress in areas like telehealth and data modernization. Collaboration with stakeholders remains crucial.
Trump revokes Biden’s executive order on responsible AI development
January 21, 2025 / Trump / Biden / AI Executive Order
President Trump revoked Biden’s 2023 executive order on responsible AI development, halting initiatives like HHS’s AI safety program, strategic AI frameworks for healthcare, and the National AI Research Resource, raising concerns over AI’s safe integration into healthcare.
Moderna gets $590M from US government for bird flu vaccine
January 21, 2025 / Moderna Bird Flu Vaccine / mRNA-1018 H5N1 Vaccine
The U.S. government awarded Moderna $590M to develop mRNA-based vaccines for pandemic influenza, including H5N1. This funding supports late-stage development, licensure, and further clinical studies, building on Moderna’s mRNA platform advancements from COVID-19 vaccine efforts.
Biden pardons Fauci to preempt possible charges when Trump takes office
January 20, 2025 / Biden Pardons Fauci / Public Health / Political Divisions
President Biden pardoned Dr. Anthony Fauci, preempting potential charges under Trump’s administration. The pardon underscores ongoing political divisions surrounding the U.S. COVID-19 response while emphasizing gratitude for Fauci’s public health contributions.
House GOP wish list includes biopharma priorities
January 17, 2025 / Biopharma Policy Priorities / IRA Drug Price Negotiation Reform / House GOP Busget
The House GOP’s budget reconciliation wishlist includes biopharma priorities such as revising the IRA drug price negotiation program and reinstating immediate R&D tax expensing, aiming to support innovation and industry growth.